HighVista Strategies LLC — 13F Holdings & Portfolio
CIK 1335325 · latest 13F-HR filed 2026-05-15
HighVista Strategies LLC manages $362.2M in 13F-reported U.S. long-equity assets across 156 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are DBC (8.45%), ABVX (3.48%), PRAX (2.34%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 35 new positions, exited 24, added to 44, and trimmed 71.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$362.2M
Long-equity book
156
Distinct positions
2026-03-31
Filed 2026-05-15
+35 / −24 / ↑44 / ↓71
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- INVESCO DB COMMDY INDX TRCK$7.0M +29.5%
- TYRA BIOSCIENCES INC$4.1M +445.2%
- ABIVAX SA$2.9M +29.5%
- DYNE THERAPEUTICS INC$2.1M +184.3%
- AMYLYX PHARMACEUTICALS INC$2.0M +69.6%
Top Trims
- VIRIDIAN THERAPEUTICS INC-$9.0M -77.3%
- STRUCTURE THERAPEUTICS INC-$7.5M -55.5%
- COGENT BIOSCIENCES INC-$4.4M -36.6%
- OLEMA PHARMACEUTICALS INC-$4.3M -71.0%
- MAZE THERAPEUTICS INC-$4.1M -57.8%
New Positions
- ORUKA THERAPEUTICS INC$3.9M
- MOONLAKE IMMUNOTHERAPEUTICS$3.6M
- DEFINIUM THERAPEUTICS INC$3.5M
- NURIX THERAPEUTICS INC$3.5M
- INVENTIVA SA$3.4M
Exited Positions
- CIDARA THERAPEUTICS INC$5.1M
- ARCELLX INC$4.9M
- AGIOS PHARMACEUTICALS INC$4.0M
- APELLIS PHARMACEUTICALS INC$3.8M
- AVIDITY BIOSCIENCES INC$2.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | INVESCO DB COMMDY INDX TRCK | DBC | 46138B103 | $30.6M | 8.45% | 1,057,238 | SH |
| 2 | ABIVAX SA | ABVX | 00370M103 | $12.6M | 3.48% | 113,254 | SH |
| 3 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $8.5M | 2.34% | 26,323 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $7.6M | 2.09% | 197,051 | SH |
| 5 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $7.4M | 2.04% | 146,264 | SH |
| 6 | VAXCYTE INC | PCVX | 92243G108 | $7.2M | 2.00% | 124,647 | SH |
| 7 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $6.7M | 1.86% | 69,309 | SH |
| 8 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $6.0M | 1.66% | 114,307 | SH |
| 9 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $6.0M | 1.65% | 123,909 | SH |
| 10 | NUVALENT INC | NUVL | 670703107 | $5.8M | 1.60% | 56,602 | SH |
| 11 | IMMUNOVANT INC | IMVT | 45258J102 | $5.6M | 1.54% | 225,139 | SH |
| 12 | SOLENO THERAPEUTICS INC | SLNO | 834203309 | $5.5M | 1.53% | 165,227 | SH |
| 13 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $5.0M | 1.39% | 131,304 | SH |
| 14 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $4.9M | 1.35% | 352,085 | SH |
| 15 | AMAZON COM INC | AMZN | 023135106 | $4.7M | 1.29% | 22,397 | SH |
| 16 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $4.3M | 1.18% | 173,595 | SH |
| 17 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $4.2M | 1.16% | 421,881 | SH |
| 18 | INSMED INC | INSM | 457669307 | $4.0M | 1.10% | 24,316 | SH |
| 19 | NVIDIA CORPORATION | NVDA | 67066G104 | $3.9M | 1.08% | 22,420 | SH |
| 20 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $3.9M | 1.07% | 78,911 | SH |
| 21 | CYTOKINETICS INC | CYTK | 23282W605 | $3.9M | 1.07% | 58,643 | SH |
| 22 | LIQUIDIA CORPORATION | LQDA | 53635D202 | $3.8M | 1.04% | 99,744 | SH |
| 23 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $3.7M | 1.03% | 441,573 | SH |
| 24 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $3.7M | 1.02% | 52,464 | SH |
| 25 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $3.7M | 1.02% | 49,560 | SH |
| 26 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $3.6M | 1.00% | 193,955 | SH |
| 27 | ARGENX SE | ARGX | 04016X101 | $3.6M | 0.99% | 4,918 | SH |
| 28 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $3.6M | 0.99% | 33,852 | SH |
| 29 | PALISADE BIO INC | PALI | 696389402 | $3.5M | 0.98% | 2,019,326 | SH |
| 30 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $3.5M | 0.97% | 185,856 | SH |
| 31 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $3.5M | 0.97% | 226,546 | SH |
| 32 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $3.5M | 0.95% | 20,437 | SH |
| 33 | INVENTIVA SA | IVA | 46124U107 | $3.4M | 0.94% | 615,666 | SH |
| 34 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $3.3M | 0.92% | 182,929 | SH |
| 35 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $3.0M | 0.83% | 35,761 | SH |
| 36 | GH RESEARCH PLC | GHRS | G3855L106 | $3.0M | 0.83% | 213,212 | SH |
| 37 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $3.0M | 0.82% | 35,587 | SH |
| 38 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $3.0M | 0.82% | 99,850 | SH |
| 39 | ERASCA INC | ERAS | 29479A108 | $2.9M | 0.81% | 181,069 | SH |
| 40 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $2.9M | 0.80% | 91,931 | SH |
| 41 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $2.9M | 0.79% | 73,102 | SH |
| 42 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $2.9M | 0.79% | 49,050 | SH |
| 43 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $2.8M | 0.78% | 89,397 | SH |
| 44 | VERA THERAPEUTICS INC | VERA | 92337R101 | $2.8M | 0.77% | 69,241 | SH |
| 45 | PHARVARIS N V | PHVS | N69605108 | $2.8M | 0.76% | 97,866 | SH |
| 46 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $2.6M | 0.72% | 134,229 | SH |
| 47 | ALKERMES PLC | ALKS | G01767105 | $2.6M | 0.71% | 73,189 | SH |
| 48 | ALUMIS INC | ALMS | 022307102 | $2.5M | 0.69% | 112,929 | SH |
| 49 | MICROSOFT CORP | MSFT | 594918104 | $2.4M | 0.66% | 6,457 | SH |
| 50 | EYEPOINT INC | EYPT | 30233G209 | $2.4M | 0.65% | 183,037 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $362.2M | 156 | 0001172661-26-002079 |
| 2025-12-31 | 2026-02-17 | $388.3M | 145 | 0001172661-26-000882 |
| 2025-09-30 | 2025-11-14 | $408.0M | 148 | 0001172661-25-004799 |